エクソンキャプチャと超並列配列決定することにより腫瘍標本における体細胞遺伝子変異を検出する

Executive Industry Relevance

Targeted exon sequencing enables biopharma R&D to detect low-frequency somatic mutations in heterogeneous tumor samples, supporting early-stage target validation and mechanistic de-risking. By providing deep coverage of oncogenes and tumor suppressor genes, this method enhances predictive confidence in preclinical models and informs lead identification strategies. Its compatibility with FFPE specimens facilitates translational continuity from discovery through preclinical validation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by identifying sequence mutations, insertions, deletions, and copy number alterations across 279 cancer-related genes.
• Operational Value: Supports biological de-risking through high-sensitivity detection of low-frequency variants in heterogeneous samples.
• Scientific Value: Facilitates pathway clarification by detecting select structural rearrangements in addition to point mutations.

Screening & Assay Development

• Scientific Value: Generates quantitative, exon-level sequence data enabling standardized assessment of mutation burden and allelic frequency.
• Operational Value: Barcoded multiplexing allows parallel processing of tumor-normal pairs, improving assay reproducibility and throughput.
• Scientific Value: Deep coverage enhances sensitivity for detecting subclonal mutations, supporting reliable compound screening in disease-relevant models.

Translational & Preclinical Research

• Scientific Value: Detects copy number gains and losses between tumor and normal pairs, informing mechanistic models of oncogene amplification or tumor suppressor loss.
• Operational Value: Enables longitudinal monitoring of genetic alterations in preclinical models, supporting risk-adjusted advancement decisions.
• Scientific Value: Provides mutation data correlative with phenotypic responses, aiding translational biomarker alignment.

Pipeline & Workflow Integration

This method integrates into the discovery continuum by enabling hypothesis-driven target validation, feeding into lead identification through mutation profiling, and supporting preclinical work via longitudinal genetic monitoring.

• Discovery Biology: Supports hypothesis testing and pathway clarification by detecting somatic alterations in cancer-associated genes.
• Screening: Delivers quantitative, reproducible outputs essential for assay standardization and compound evaluation in multiplexed formats.
• Analytics: Provides allele-specific read counts and copy number inferences enabling statistical comparison across conditions.
• Translational Research: Connects discovery findings to preclinical continuity through detection of mutations correlative with drug response.
• Enterprise Reuse: Barcoded library preparation enables reuse across multiple projects and tumor types, maximizing platform utilization.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by detecting low-frequency mutations and copy number alterations missed by low-depth methods.
• Operational Value: Standardized workflow with barcoding and multiplexing improves reproducibility and reduces per-sample cost.
• Strategic Value: Informs go/no-go decisions by revealing oncogenic drivers and resistance mechanisms early in discovery.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on mutation prevalence and functional impact.

Implementation Considerations

• Requires expertise in nucleic acid library preparation, hybridization-based capture, and next-generation sequencing data analysis.
• Dependent on access to massively parallel sequencing platforms and biotinylated oligonucleotide probes for target enrichment.
• Necessitates standardized protocols for FFPE and fresh frozen tissue processing to ensure DNA quality and library yield.
• Requires bioinformatics infrastructure for alignment, variant calling, and copy number inference from sequencing data.
• Performance limited by input DNA quantity and quality, particularly in degraded FFPE samples affecting capture efficiency.

Biopharma FAQs